Wide Ranks

CYTH

Cyclo Therapeutics, Inc.

0.7200

Top Statistics
Market Cap 20 M Forward PE -1.09 Revenue Growth 5.10 %
Current Ratio 0.45 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.9230 Enterprise / Revenue 17.23 Price To Sales Trailing12 Months 18.29
Profitability
Profit Margins 0.00 % Operating Margins -4577.99 %
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.0390 Total Debt 2 M
Total Debt To Equity Current Ratio 0.45 Book Value Per Share 0.1670
All Measures
Short Ratio 382.00 % Message Board Id finmb_3103504 Fax 321 244 8351
Shares Short Prior Month 167192 City Gainesville Uuid a5c907ad-6995-37ac-ac71-96d00d122983
Previous Close 0.6790 First Trade Date Epoch Utc 957 M Book Value 0.1670
Beta -0.3810 Total Debt 2 M Volume 14805
Price To Book 4.31 Last Split Date 1 B Fifty Two Week Low 0.5900
Total Cash Per Share 0.0390 Total Revenue 1 M Shares Short Previous Month Date 1 B
Target Median Price 0.9500 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -4577.99 % Target Mean Price 0.9500 Net Income To Common -20738080
Short Percent Of Float 0.0046 Implied Shares Outstanding 28 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 23970 Average Volume10days 23970
Total Cash 1 M Next Fiscal Year End 1 B Revenue Per Share 0.0460
Held Percent Insiders 0.4008 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.6790 Target Low Price 0.9500
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.7298 Open 0.6800
Free Cashflow -10790528 State FL Dividend Yield 0.00 %
Return On Assets -2.82 Time Zone Short Name EST Trailing Eps -0.9000
Day Low 0.6390 Address1 6714 NW 16th Street Shares Outstanding 28 M
Price Hint 4 Target High Price 0.9500 Website https://cyclotherapeutics.com
52 Week Change -0.5000 Average Volume 35585 Forward Eps -0.6600
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 12.30 %
Last Split Factor 1:100 Regular Market Day High 0.7200 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 2.12 Day High 0.7200
Shares Short 114417 Regular Market Open 0.6800 Industry Key drug-manufacturers-specialty-generic
Earnings Growth 0.00 % Enterprise To Revenue 17.23 Revenue Growth 5.10 %
Shares Percent Shares Out 0.0040 Operating Cashflow -18366346 Currency USD
Time Zone Full Name America/New_York Market Cap 20 M Is_nasdaq_100 False
Zip 32653 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Cyclo Therapeutics, Inc. Regular Market Day Low 0.6390 Held Percent Institutions 0.1317
Current Price 0.7200 Address2 Suite B Enterprise To Ebitda -0.9230
Financial Currency USD Current Ratio 0.45 Gross Margins 91.56 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 2 Country United States
Float Shares 15 M Two Hundred Day Average 1.14 Enterprise Value 19 M
Price To Sales Trailing12 Months 18.29 Forward PE -1.09 Regular Market Volume 14805
Ebitda -21140932 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases.

The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.

It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019.

Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.